Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MST. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart. 2014;1(1):e000177.

Article  PubMed  PubMed Central  Google Scholar 

Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107(23):2932–7.

Article  PubMed  Google Scholar 

Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427–520.

Article  PubMed  Google Scholar 

Nahlawi M, Waligora M, Spies SM, Bonow RO, Kadish AH, Goldberger JJ. Left ventricular function during and after right ventricular pacing. J Am Coll Cardiol. 2004;44(9):1883–8.

Article  PubMed  Google Scholar 

Karpawich PP, Justice CD, Cavitt DL, Chang CH. Developmental sequelae of fixed-rate ventricular pacing in the immature canine heart: an electrophysiologic, hemodynamic, and histopathologic evaluation. Am Heart J. 1990;119(5):1077–83.

Article  CAS  PubMed  Google Scholar 

Nielsen JC, Bøttcher M, Toftegaard Nielsen T, Pedersen AK, Andersen HR. Regional myocardial blood flow in patients with sick sinus syndrome randomized to long-term single chamber atrial or dual chamber pacing—effect of pacing mode and rate. J Am Coll Cardiol. 2000;35(6):1453–61.

Article  CAS  PubMed  Google Scholar 

Karpawich PP, Rabah R, Haas JE. Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block. Pacing Clin Electrophysiol. 1999;22(9):1372–7.

Article  CAS  PubMed  Google Scholar 

Schwerg M, Dreger H, Poller WC, Dust B, Melzer C. Efficacy of optimal medical therapy and cardiac resynchronization therapy upgrade in patients with pacemaker-induced cardiomyopathy. J Interv Card Electrophysiol. 2015;44(3):289–96.

Article  PubMed  Google Scholar 

Dor O, Haim M, Barrett O, Novack V, Konstantino Y. Incidence and clinical outcomes of pacing induced cardiomyopathy in patients with normal left ventricular systolic function and atrioventricular block. Am J Cardiol. 2020;128:174–80.

Article  PubMed  Google Scholar 

Boyle TA, Pothineni NVK, Austin M, Shivamurthy P, Markman T, Guandalini G, et al. Incidence and predictors of pacing-induced right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2024;17(10):e013070.

Article  PubMed  Google Scholar 

Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016;13(12):2272–8.

Article  PubMed  Google Scholar 

Tayal B, Fruelund P, Sogaard P, Riahi S, Polcwiartek C, Atwater BD, et al. Incidence of heart failure after pacemaker implantation: a nationwide Danish registry-based follow-up study. Eur Heart J. 2019;40(44):3641–8.

Article  PubMed  Google Scholar 

Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm. 2014;11(9):1619–25.

Article  PubMed  Google Scholar 

Kim SS, Park HW. New insights into pacing induced cardiomyopathy. Rev Cardiovasc Med. 2024. https://doi.org/10.31083/j.rcm2504118.

Article  PubMed  PubMed Central  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

Article  CAS  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39.

Article  CAS  PubMed  Google Scholar 

Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140.

Article  CAS  PubMed  Google Scholar 

Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol. 2022;21(1):45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carluccio E, Biagioli P, Reboldi G, Mengoni A, Lauciello R, Zuchi C, et al. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovasc Diabetol. 2023;22(1):235.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nilsson CN, Ersbøll MK, Gustafsson F. Haemodynamic effects of Sodium-glucose cotransporter 2 inhibitor treatment in chronic heart failure patients. Card Fail Rev. 2024. https://doi.org/10.15420/cfr.2023.25.

Article  PubMed  PubMed Central  Google Scholar 

Acquaro M, Scelsi L, Mascolo C, Pelosi C, Greco A, Turco A, et al. Dapagliflozin effects on left ventricular remodeling and filling pressures in heart failure with reduced ejection fraction. J Am Soc Echocardiogr. 2025;38(5):395–403.

Article  PubMed  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

Article  CAS  PubMed  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.

Article  PubMed  Google Scholar 

Cautela J, Alexandre J. SGLT2 inhibitors in cancer patients: a paradigm shift in cardio-oncology? Eur J Prev Cardiol 2025;

Bhatti AW, Patel R, Dani SS, Khadke S, Makwana B, Lessey C, et al. SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes. JACC CardioOncol. 2024;6(6):863–75.

Article  PubMed  PubMed Central  Google Scholar 

Baigent C, Emberson JonathanR, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–801.

Article  Google Scholar 

Akerström F. The importance of avoiding unnecessary right ventricular pacing in clinical practice. World J Cardiol. 2013;5(11):410.

Article  PubMed  PubMed Central  Google Scholar 

Chung MK, Patton KK, Lau CP, Dal Forno ARJ, Al-Khatib SM, Arora V, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023;20(9):e17-91.

Article  PubMed  PubMed Central  Google Scholar 

Vijayaraman P, Herweg B, Dandamudi G, Mittal S, Bhatt AG, Marcantoni L, et al. Outcomes of His-bundle pacing upgrade after long-term right ventricular pacing and/or pacing-induced cardiomyopathy: insights into disease progression. Heart Rhythm. 2019;16(10):1554–61.

Article  PubMed  Google Scholar 

Gwag HB, Chun KJ, Hwang JK, Park KM, On YK, Kim JS, et al. Comparison of de novo versus upgrade cardiac resynchronization therapy; focused on the upgrade for pacing-induced cardiomyopathy. Yonsei Med J. 2017;58(4):703.

Article  PubMed  PubMed Central  Google Scholar 

Agha MS, Schaich CL, Rikhi R, Hari K, Bodziock G, Bhave P. Effect of medical therapy on reducing the risk of pacing-induced cardiomyopathy. J Am Heart Assoc. 2025. https://doi.org/10.1161/JAHA.124.040415.

Article  PubMed